Gilvetmab

Gilvetmab is a potent caninized anti-PD-1 monoclonal antibody. Gilvetmab blocks the interaction between PD-1 and its ligand PD-L1/L2. Gilvetmab can be used in malignant melanoma and mast cell tumor research[1][2][3].

Product Specifications

CAS Number

[1808081-43-7]

UNSPSC

12352203

Hazard Statement

H360-H372

Target

PD-1/PD-L1

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/gilvetmab.html

Purity

99.37

Solubility

10 mM in DMSO

Smiles

[Gilvetmab]

Molecular Weight

(147.71 kDa)

Precautions

P260-P264-P270-P280-P405-P501

References & Citations

[1]Magee K, et al. Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting. PLoS One. 2021 Aug 12;16 (8) :e0255798.|[2]Xia YY, et al. Limited Clinical Efficacy with Potential Adverse Events in a Pilot Study of Autologous Adoptive Cell Therapy in Canine Oral Malignant Melanoma. Vet Sci. 2024 Mar 28;11 (4) :150.|[3]Wang J, et al. Current Review of Monoclonal Antibody Therapeutics in Small Animal Medicine. Animals (Basel) . 2025 Feb 7;15 (4) :472.